News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
CureVac Announces Phase I/IIa Clinical Study Data Of Its mRNA Cancer Immunotherapy In Prostate Cancer Published In The Journal For Immunotherapy Of Cancer 7/7/2015
Abide Therapeutics Announces First Subject Dosed In First-In-Human Clinical Study Of ABX-1431, An Investigational Endocannabinoid System Modulator 7/7/2015
Enzymotec Announces Investigator Initiated Clinical Trial Of Vayarin In Managing ADHD In Children With Epilepsy 7/7/2015
FDA Bestows Breakthrough Therapy Designation on Dyax Corp. (DYAX)'s HAE Drug As Suitors Circle 7/7/2015
Dyax Corp. (DYAX) Receives FDA Breakthrough Therapy Designation For DX-2930 For Prevention Of Attacks Of Hereditary Angioedema 7/7/2015
Blaze Bioscience Inc.’s BLZ-100 Receives Orphan Drug Designation From FDA For Brain Cancer 7/7/2015
WCCT Global Completes Multiple Ethnobridging Studies At Phase I CPUs 7/7/2015
EXCLUSIVE: DNAnexus, Inc., Stanford University Genomic Catalog Will Accelerate Science in the Field, Says CEO 7/7/2015
Johnson & Johnson (JNJ) HIV Vaccine Blocks Virus in 50% of Monkeys, Soon to Start Human Trial in 400 7/6/2015
XBiotech USA (XBIT) Treats First Patient In Phase I/II Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus 7/6/2015
Catabasis Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 7/6/2015
PhytoTech Medical Ltd (ASX:PYL) Oral Formulations Advance Towards Phase 1 Clinical Trials 7/6/2015
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Arrowhead Research Corporation (ARWR) Initiates Dosing Of ARC-AAT In Patients With Alpha-1 Antitrypsin Deficiency 7/2/2015
EXCLUSIVE: Pediatric Patients Could Benefit Most From New Oncoceutics Cancer Drug, Says Exec 7/2/2015
Provectus Biopharmaceuticals Inc.’ Data On PV-10 For Chemoablation Of Liver Cancers Presented At ESMO 17th World Congress On Gastrointestinal Cancer 7/2/2015
Immunovaccine Inc. Publishes Clinical Results With DPX-Survivac In Combination With An Immune-Modulating Compound 7/2/2015
Vitae Pharma (VTAE)’ Diabetes Drug Fails Mid-Stage Trial, the Second Drug in Less Than Six Months to Fail 7/1/2015
Rock Creek Pharmaceuticals Reports Human Proof Of Principle Study Of Lead Compound Demonstrating Inhibition Of Inflammatory Markers In White Blood Cells 7/1/2015
MediciNova, Inc. Announces The Completion Of Enrollment In Clinical Trial Of MN-166 (Ibudilast) In Alcohol Dependence 7/1/2015
Intralink-Spine Announces Long-Term Large-Animal Testing Shows Positive Results Related To Lower Back Pain 7/1/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
Egalet Announces Top-Line Results From Oral Human Abuse Liability Study Of Egalet-002 6/30/2015
Aridis Pharmaceuticals Receives FDA Fast Track Designation For Aerucin For Treating Hospital-Acquired And Ventilator-Associated Pneumonia 6/30/2015
Immunovaccine Inc. Initiates Clinical Trial With DPX-RSV Vaccine 6/30/2015
SillaJen Publishes Clinical Data Demonstrating Safe Administration Of Multiple Intravenous Doses Of Oncolytic Virus In Patients With Metastatic Colorectal Cancer 6/29/2015
Egalet Jumps As Lead Drug Is Less Likely To Be Abused Than Other Painkillers 6/29/2015
RedHill Biopharma Ltd. (RDHL) Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma 6/29/2015
Comvita Human Intervention Trial Demonstrates Positive Effect Of Olive Leaf Extract On Cardiovascular Disease 6/29/2015
Bioiberica To Trial A New Compound On Human Subjects That Prevents Memory Loss In Patients With Mild Alzheimer's 6/29/2015
Adocia And Eli Lilly (LLY) Report Positive Phase 1b Topline Results On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro In Patients With Type 1 Diabetes 6/29/2015
ProQR Therapeutics B.V. (PRQR) Announces Enrollment Has Started In Global Phase 1b Study Of QR-010 In Cystic Fibrosis Patients 6/26/2015
StemCells (STEM) Reports Top Line Results For Its Phase I/II Study In Dry Age Related Macular Degeneration 6/26/2015
Neos Therapeutics Presents Data At ASCP Annual Meeting For Investigational XR-ODT For Treatment Of ADHD 6/25/2015
CSL Behring Announces Pivotal Data Of Novel rVIII-SingleChain Therapy In Adolescents And Adults With Hemophilia A 6/24/2015
Agios (AGIO) Announces First Patient Dosed With AG-881 In Phase 1 Study In Patients With Advanced Solid Tumors With An IDH Mutation 6/24/2015
MediciNova, Inc. Announces Presentation Of Interim Data From Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence At The 38th Annual RSA (Research Society On Alcoholism) Scientific Meeting 6/24/2015
Catalyst Biosciences Announces Positive Results From A Phase 1 Clinical Trial Of Its Next Generation Coagulation Factor VIIa In Patients With Hemophilia A Or B And Preclinical Results From Its Factor IX And Factor Xa Programs 6/24/2015
AveXis Gains Orphan Drug Designation From European Medicines Agency For Gene Therapy Treatment In Spinal Muscular Atrophy 6/24/2015
Alnylam (ALNY) Reports New Positive Clinical Data For ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders 6/24/2015
NeuroRx Announces First Human Trial Results Targeting Sustained Treatment Of Bipolar Depression & Suicidality 6/24/2015
Vical  (VICL) Herpes Vaccine Clinical Trial Disappoints with "Confounding Results" 6/24/2015
Epizyme (EPZM) Surges on NHL Cancer Drug Data, As Analysts Laud Early Successes 6/24/2015
RestorGenex Announces Prostate Cancer Data On RES-529, A Dual TORC1/TORC2 Inhibitor 6/23/2015
TapImmune Inc. (TPIV) Reports Robust Immune Responses Generated In 19 Of 20 Evaluable HER2/Neu Breast Cancer Patients 6/23/2015
BIND Therapeutics (BIND) Announces FDA Authorization Of First-in-Human Clinical Trial With AstraZeneca PLC (AZN)’s Aurora B Kinase Inhibitor Accurin AZD2811 6/23/2015
ERYtech Pharma Announces Two Positive DSMB Reviews 6/23/2015
Epizyme (EPZM) Announces Additional Positive Data From Ongoing Phase 1 Study Of Tazemetostat (EPZ-6438) In Relapsed Or Refractory Non-Hodgkin Lymphoma 6/22/2015
Karyopharm (KPTI) Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At International Conference On Malignant Lymphoma 6/22/2015
ChromaDex, Inc. Announces A Collaborative Human Clinical Study On NIAGEN With The University of Colorado Boulder 6/18/2015
Admune Announces The First-In-Human Study Of Heterodimeric IL-15 (Hetil-15) With Broad Applications For Cancer Immunotherapy 6/18/2015
Heptares Announces Positive Outcome Of Phase 1A Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015
Prothena (PRTA) Presents Clinical Results Demonstrating Robust, Rapid Reduction In Levels Of Free Serum Alpha-Synuclein Of Up To 96% After Single Dose Of PRX002, Novel Protein Immunotherapy For Parkinson's Disease 6/17/2015
Catabasis Pharmaceuticals, Inc. Initiates Movedmd, A Phase I/II Trial Of CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 6/17/2015
Sosei Subsidiary Heptares Announces Positive Outcome Of Phase 1a Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015
Quartet Medicine Announces Neuron Publication Validating Role Of The BH4 Pathway In Chronic Neuropathic And Inflammatory Pain 6/17/2015
Minerva Neurosciences, Inc. (NERV) Provides Update On MIN-202, Selective Orexin-2 Receptor Antagonist 6/16/2015
XOMA (US) LLC (XOMA) Receives Orphan Drug Designation For XOMA 358 From FDA For Treatment Of Congenital Hyperinsulinism (HI) 6/16/2015
Neovacs SA Initiates Clinical Program In Dermatomyositis 6/16/2015
Phase I Data Published in The Lancet Show Boehringer Ingelheim's Idarucizumab Reverses Anticoagulant Effects of Dabigatran 6/16/2015
Apexigen Doses First Patient In Phase 1 Clinical Trial Of Its Immuno-Oncology Therapeutic Antibody APX005M 6/16/2015
Protalex, Inc. (PRTX) Receives Orphan Drug Designation From FDA For PRTX-100 To Treat Immune Thrombocytopenia 6/16/2015
PNP Therapeutics, Inc. Receives Orphan Drug Status For Gedeptin 6/16/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cited In New Journal Article On Results Of Phase I/II Clinical Trial Of Dendritic Cell Immunotherapy For Prostate Cancer 6/15/2015
EnGeneIC And Asbestos Diseases Research Institute Announce Encouraging Results From Mesomir-1 Phase 1 Trial In Late Stage Mesothelioma Patients 6/15/2015
Laurent Pharmaceuticals Announces Positive Phase 1b Topline Results For LAU-7b In Cystic Fibrosis 6/15/2015
Amarillo Biosciences (AMAR) Announces Presentation Of Eltoprazine Phase I/IIa Clinical Data At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
Genzyme (GENZ) Initiates Phase I/II Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients 6/15/2015
Principia Biopharma Presents Full Phase 1 Clinical Trial Results For PRN1008, A Novel Reversible Covalent BTK Inhibitor, Supporting Further Clinical Development In Autoimmune And Inflammatory Diseases 6/15/2015
bluebird bio (BLUE) Reports New Beta-Thalassemia Major And Severe Sickle Cell Disease Data From HGB-205 Study At European Hematology Association 6/15/2015
Karyopharm (KPTI) Presents Hematologic Cancer Data On Lead Drug Candidate Selinexor At European Hematology Association Annual Meeting 6/15/2015
AbbVie (ABBV) Release: Phase 1b Study Of Investigational Treatment Venetoclax With Rituximab Shows Clinical Response In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia 6/12/2015
Merrimack (MACK) Announces Expansion Of MM-398 (nal-IRI) Imaging Study To Patients With Metastatic Breast Cancer 6/12/2015
Calithera Biosciences, Inc. (CALA) Reports Phase I Data For CB-839 In Patients With Acute Leukemias At The 20th Congress Of The European Hematology Association 6/12/2015
TG Therapeutics, Inc. (MHA) To Present Clinical Data On TG-1101 And TGR-1202 At The 20th Congress Of The European Hematology Association And The 13th International Congress On Malignant Lymphoma 6/12/2015
Prothena (PRTA)'s NEOD001 Protein Immunotherapy Clinical Data Highlighted In Oral Presentation At The 20th Congress Of The European Hematology Association 6/12/2015
Cellectar Biosciences  (NVLT) Announces CLR1502 Development Program To Be Classified As Combination Product By FDA 6/12/2015
Agios (AGIO) Announces New Data from Ongoing Phase 1 Trial Of AG-120 Showing Durable Clinical Activity In Patients With Advanced Hematologic Malignancies 6/12/2015
Agios (AGIO) Announces New Data From Ongoing Phase 1 Dose Escalation And Expansion Trial Of AG-221 Showing Durable Clinical Activity In Patients With Advanced Hematologic Malignancies 6/12/2015
Corbus Announces FDA Orphan Drug Designation For Resunab For The Treatment Of Systemic Sclerosis (Scleroderma) 6/12/2015
Rock Creek Pharmaceuticals Announces Clinical Update 6/11/2015
ForSight VISION5's Clinical Data Demonstrating 6-Month IOP-Lowering From A Single Dose Presented At World Glaucoma Congress; Company Completes Enrollment Of Phase 2 Dose-Ranging Study 6/11/2015
Celyad Completes 30-Day Safety Follow-Up Of First Patient In NKG2D Phase I Trial 6/11/2015
Actinogen Limited Release: Excellent Research Progress With Xanamem – A Promising Alzheimers Drug 6/11/2015
Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study With Promising NMDA Receptor Antagonist D-Methadone 6/10/2015
Xencor Reports Complete Data Results On Xmab5871 Program At European League Against Rheumatism (EULAR) 2015 Annual Meeting 6/10/2015
BerGenBio AS Initiates NSCLC Clinical Trial With BGB324 In Combination With erlotinib 6/10/2015
Prothena (PRTA) Announces First Human Dosed In Phase I Study Of PRX003 For The Treatment Of Psoriasis And Other Inflammatory Diseases 6/10/2015
FDA Awards Isarna Therapeutics Orphan Drug Designation For ISTH0036 To Improve Glaucoma Treatment Outcome 6/10/2015
Selecta Initiates Phase 1 Clinical Program Of SEL-212, Designed As The First Non-Immunogenic Biologic Treatment For Gout 6/10/2015
Arrowhead Research Corporation (ARWR) Receives Orphan Drug Designation For ARC-AAT 6/10/2015
Oncolytics Biotech Inc. (ONC.TO) Provides Update At AGM On Planned Registration Program For REOLYSIN 6/9/2015
Prothena (PRTA) To Present Clinical Results From Its Phase I Single Ascending Dose Study Of PRX002 At 19th International Congress Of Parkinson's Disease And Movement Disorders 6/8/2015
FDA Grants Breakthrough Designation to Genzyme (GENZ)’s Experimental ASMD Treatment 6/8/2015
Celator Pharmaceuticals, Inc. Announces Expansion of Clinical Study In Patients With Untreated Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) At High-Risk Of Treatment-Related Mortality 6/8/2015
Merck's KEYTRUDA (pembrolizumab) Receives Conditional Approval In Canada For The Treatment Of Advanced Melanoma 6/8/2015
BeiGene Co.,Ltd Enrolls First Patient In Phase I Study Of BGB-A317, A Humanized Anti-PD-1 Monoclonal Antibody 6/8/2015
PhaseBio Announces Positive Data For Type 2 Diabetes Treatments PE0139 And PB1023 6/8/2015
Capricor Therapeutics, Inc. Announces Receipt Of FDA Clearance For The Phase I/II Study Of CAP-1002 For The Treatment Of Duchenne Muscular Dystrophy Related Cardiomyopathy 6/8/2015
Advaxis, Inc.'s Cancer Immunotherapy Delays Progression Of HER2+ Canine Osteosarcoma 6/8/2015
Osama Hamdy, MD PhD, Presented Results Of Metagenics Inc.' Ultra Glucose Control On Glucose Response And GLP-1 At American Diabetes Association 2015 6/8/2015
Asterias Biotherapeutics Announces First Patient Treated In Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury 6/8/2015
Dyax Corp. (DYAX) Presents Phase 1b DX-2930 Data At The 2015 European Academy of Allergology and Clinical Immunology Annual Congress 6/8/2015
Ligand Pharmaceuticals Inc. (LGND) Announces Favorable Results From Phase 1b Trial With LGD-6972 In Type 2 Diabetes And Plans To Initiate A Phase 2 Trial 6/8/2015
Synageva BioPharma (GEVA) Completes Targeted Enrollment In Phase 1/2 Trial With SBC-103 For Mucopolysaccharidosis IIIB 6/5/2015
Retrophin (RTRX) Receives Fast Track Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration 6/5/2015
ASCO15 EXCLUSIVE: Berg’s Lead Cancer Drug May Shift Cancer Metabolism, Says CEO 6/4/2015
Regulus (RGLS) Initiates Phase I Clinical Study Of RG-012, A microRNA Therapeutic In Development For The Treatment Of Alport Syndrome 6/4/2015
Seattle Children's Opens Patient Enrollment For First Tumor Paint Clinical Trial For Children With Brain Cancer 6/4/2015
Gradalis Inc. Announces Presentation Of Data From A Pilot Study Of Vigil Cancer Vaccine In Ewing’s Sarcoma 6/4/2015
Catabasis Pharmaceuticals, Inc. Announces Preliminary Phase I Data For Hypercholesterolemia Product Candidate CAT-2054 6/4/2015
Catabasis Pharmaceuticals, Inc. Announces Preliminary Phase 1 Data For Hypercholesterolemia Product Candidate CAT-2054 6/4/2015
BEAT BioTherapeutics’ BB-R12 Provides Significant Improvement In Cardiac Function In Heart Failure Study 6/4/2015
Blaze Bioscience Inc. Announces Open Enrollment For Phase 1 Clinical Trial Of Tumor Paint BLZ-100 In Children With Brain Cancer 6/4/2015
Humanetics Granted FDA Clearance To Proceed With Cancer Treatment Study 6/3/2015
EXCLUSIVE: Nektar Therapeutics (NKTR), University of Texas MD Anderson Cancer Center Team Up on Phase 1/2 Trial of NKTR-214 6/2/2015
Merrimack (MACK) Announces Data From An Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile For MM-398 In High-Grade Glioma 6/2/2015
Minervax Initiates Phase I Clinical Trial With Innovative Group B Streptococcal (GBS) Vaccine To Prevent Life-Threatening Infections In Newborns 6/2/2015
ASCO15: Dicerna (DRNA) Presents Preliminary Safety And Efficacy Data From DCR-MYC Phase 1 Study In Patients With Advanced Solid Tumors At The 2015 ASCO Annual Meeting 6/2/2015
ASCO15: Prothena (PRTA) Presents Compelling New Data From Ongoing Phase I/II Study Of NEOD001 In Patients With AL Amyloidosis At 2015 ASCO Annual Meeting 6/2/2015
ASCO15: Kite Pharma (KITE) Presents Clinical Biomarker Results in Patients Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy at the 2015 ASCO Annual Meeting 6/2/2015
ASCO15: Cleveland Biolabs Inc. (CBLI) Releases Entolimod Phase 1 Study Findings At ASCO 6/2/2015
Aphios Completes Enrollment In Phase I/II Clinical Trial Towards An HIV Cure 6/2/2015
Aptose Biosciences Granted Orphan Drug Designation By The U.S. FDA For APTO-253 In Acute Myeloid Leukemia 6/2/2015
H. Lee Moffitt Cancer Center & Research Institute Announces First Patient In Nation Treated With KTE-C19 In Kite Pharma (KITE)'s Clinical Trial For Non-Hodgkin's Lymphoma 6/2/2015
Lipocine Inc. (LPCN) Receives FDA Orphan Drug Designation For LPCN 1107, An Oral Product Candidate For The Prevention Of Preterm Birth 6/2/2015
ASCO15: Analyst Calls ImmunoGen (IMGN)'s Phase I Ovarian Cancer Data "Impressive" 6/1/2015
ASCO15: Merck & Co. (MRK) Findings Presented At 2015 ASCO Annual Meeting Add To Breadth Of KEYTRUDA (Pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated In 13 Different Tumor Types 6/1/2015
ASCO15: ImmunoGen (IMGN)'s Mirvetuximab Soravtansine (IMGN853) Demonstrates Notable Single Agent Activity For Patients With Platinum-Resistant Ovarian Cancer 6/1/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Phase Ib/II Data Show Promise In Patients With Chronic Graft-Versus-Host-Disease 6/1/2015
ASCO15: Celsion Corporation (CLSN) Presents GEN-1 Immunotherapy Phase 1b Results In Recurrent Ovarian Cancer At ASCO 2015 6/1/2015
ASCO15: Calithera Biosciences, Inc. (CALA) Reports Phase I Data For CB-839 In Patients With Solid Tumors At The 2015 ASCO 6/1/2015
Astellas Pharma Inc. (ALPMY) Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) 6/1/2015
ASCO15: MacroGenics, Inc. (MGNX) Presents Updated Data From Phase I Study Of Margetuximab At ASCO Annual Meeting 2015 6/1/2015
ASCO15: Oncothyreon Inc. (ONTY) Announces Presentation Of Positive ONT-380 Data In HER2-Positive Breast Cancer At ASCO Annual Meeting And Updates Development Plan 6/1/2015
Array BioPharma, Inc. (ARRY) Release: Binimetinib And Encorafenib Combination Shows Promising Clinical Activity And Potential Differentiated Safety In BRAF-Mutant Melanoma 6/1/2015
ASCO15: Adaptimmune Announces Data From Clinical Studies Of NY-ESO-1 Specific T-Cells In Multiple Cancers At The 2015 Annual ASCO Meeting 6/1/2015
ASCO15: Curis, Inc. (CRIS) Reports CUDC-907 Data From The Ongoing Phase I Trial At The 2015 ASCO Annual Meeting 6/1/2015
ASCO15: VBL Therapeutics (VBLX) To Present Phase I/IIa Data From VB-111 In Recurrent Platinum-Resistant Mullerian Cancer At The 2015 ASCO Annual Meeting 6/1/2015
ARMO BioSciences Announces Efficacy And Safety Data For Immuno-Oncology Program With Novel Mechanism Of Action 6/1/2015
BerGenBio AS Release: BGB324 And BGB10C9 Show Promise In Models Of Pancreatic Cancer 6/1/2015
ASCO15: OncoMed Pharmaceuticals, Inc. (OMED) Presents Data From Phase Ib Trial Of Demcizumab In Pancreatic Cancer At The 2015 ASCO Annual Meeting 6/1/2015
ASCO15: OncoMed Pharmaceuticals, Inc. (OMED) Presents Updated Demcizumab Data In Non-Small Cell Lung Cancer At The 2015 ASCO Annual Meeting 6/1/2015
ASCO15: OncoMed Pharmaceuticals, Inc. (OMED) Presents Phase 1b Clinical Trial Data For Tarextumab In Small Cell Lung Cancer At The 2015 ASCO Annual Meeting 6/1/2015
ASCO15: TG Therapeutics, Inc. (MHA) Announces Presentations Of Its Proprietary Combination Of TG-1101 Plus TGR-1202 As Well As TGR-1202 As A Single Agent In Ongoing Phase I/Ib Dose Escalation Clinical Studies 6/1/2015
Immunomedics, Inc. (IMMU) Reports Promising Results With Sacituzumab Govitecan In Patients With Metastatic Gastrointestinal Cancers 6/1/2015
ASCO15: Juno Therapeutics (JUNO)'s Investigational CAR T Cell Product Candidate JCAR014 Demonstrates Encouraging Clinical Responses And Translational Insights In Patients With B-Cell Cancers 6/1/2015
Northwest Biotherapeutics (NWBO) Announces Data To Date From DCVax-Direct Phase I Trial 6/1/2015
ASCO15: AstraZeneca PLC (AZN) Presents Positive Data On AZD9291 In First-Line EGFR Mutated Lung Cancer At ASCO 2015 6/1/2015
ASCO15: Aduro Biotech (ADRO) Announces ASCO Presentation Of Encouraging Data From Ongoing Phase Ib Clinical Trial Of Its Immunotherapy For The Treatment Of Mesothelioma 6/1/2015
ASCO15: Juno Therapeutics (JUNO)'s Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses In Patients With B-Cell Cancers 6/1/2015
ASCO15: Momenta (MNTA) To Present New Data From Phase 1 Trial Of Necuparanib In Patients With Pancreatic Cancer 6/1/2015
ASCO15: TG Therapeutics, Inc. (MHA) Announces The Triple Combination Of TG-1101, TGR-1202 And Ibrutinib Is Safe And Highly Active In Patients With Advanced B-Cell Malignancies 6/1/2015
ASCO15: Targovax Releases TGO1 RAS-Mutation-Specific Immunotherapy Data At ASCO 6/1/2015
Ignyta (RXDX) Announces Phase 1 Clinical Trial Data For Entrectinib 6/1/2015
The Medicines Company (MDCO) Announces Results Of Phase 1 Study For Novel Investigational Intravenous Anesthetic, ABP-700 6/1/2015
ASCO15: Ariad (ARIA) Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer At The 2015 ASCO Meeting 6/1/2015
Infinity Pharmaceuticals Inc. (INFI) Reports Phase 1 Data Showing Clinical Activity Of Duvelisib In Treatment-Naïve Patients With Chronic Lymphocytic Leukemia 6/1/2015
Ariad (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial 6/1/2015
ASCO15: Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 6/1/2015
ASCO15: Kolltan Pharmaceuticals Inc. Announces Presentation Of KTN3379 Interim Phase 1b Data At 2015 American Society Of Clinical Oncology Annual Meeting 6/1/2015
Merck & Co. (MRK) Release: New Findings Show Durable Anti-Tumor Activity With KEYTRUDA (Pembrolizumab), Merck’s Anti-PD-1 Therapy, In Patients With Advanced Head And Neck Cancer, Regardless Of PD-L1 Expression Status 6/1/2015
ASCO15: AbbVie (ABBV) Presents Results From Phase 1 Studies Of Investigational Compound Venetoclax In Patients With Multiple Myeloma At The American Society Of Clinical Oncology Annual Meeting 6/1/2015
ASCO15: Hanmi Pharma ‘HM61713’ Demonstrated The Effect Of Tumor Volume Reduction 6/1/2015
ASCO15: Karyopharm (KPTI) Presents Clinical Data For Selinexor (KPT-330) In Patients With Recurrent Glioblastoma And Advanced Sarcomas At 2015 ASCO Annual Meeting 6/1/2015
ASCO15: DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme (GBM) At ASCO 6/1/2015
DelMar Pharmaceuticals Presents Additional Data On The Potential Of VAL-083 In The Treatment Of Temozolomide-Resistant Glioblastoma Multiforme 5/29/2015
Stemline Therapeutics, Inc. (STML) Announces Top-Line Results From Lead-In Stage Of Ongoing BPDCN Pivotal Trial 5/29/2015
Alkermes (ALKS) To Present Clinical Data On ALKS 8700 At Annual Meeting Of The Consortium Of Multiple Sclerosis Centers 5/29/2015
ASCO15: University Hospitals Case Medical Center Experts To Present Data At 51st ASCO Annual Meeting 5/29/2015
ASCO15: Portola Pharmaceuticals, Inc. Presents Updated Data From Ongoing Phase I/IIa Study Of Dual Kinase Inhibitor Cerdulatinib 5/29/2015
PDS Biotechnology Corporation Reports Positive Phase I Clinical Trial Results In Proprietary HPV-Cancer Immunotherapy 5/28/2015
XBiotech Launching Phase I/II Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus 5/28/2015
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015
TiGenix Release: Safety And Tolerability Of Cx611 Confirmed In Phase I Sepsis Challenge Trial 5/28/2015
Embera NeuroTherapeutics, Inc. Initiates Phase 1 Clinical Trial To Test EMB-001 As A Novel Treatment For Addictions 5/28/2015
Kadmon Corporation Announces Initial Phase 1b Data For Tesevatinib In Patients With Metastatic Breast Cancer 5/28/2015
Anaheim Clinical Trials (ACT) Phase I Clinical Trial Center Selected As A Subcontractor In NIH/National Institute of Allergy And Infectious Diseases (NIAID)’s Therapeutics Against Infectious Disease Initiative 5/27/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/27/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015
Genelux Corporation Announces Promising Data From Two Phase I Trials Of GL-ONC1 In Head & Neck Cancer And Mesothelioma 5/27/2015
G1 Therapeutics Announces Positive Phase Ia Data For CDK4/6 Inhibitor G1T28 5/27/2015
Cannabis Science Inc. Brings CS-TATI-1 To The FDA With Historic Collaborative Drug Development Deal With IGXBio and Its GenePro, A DNA-Based Immunotherapeutic That Recently Received FDA Approval To Enter Into Human Trials 5/27/2015
Stock Soars as bluebird bio (BLUE) Gives Sneak Peek at Promising Sickle Cell Data 5/26/2015
Principia Biopharma And University of California, San Francisco (UCSF) Scientists Announce Publication Of Seminal Paper On Reversible Covalent Drugs In Nature Chemical Biology 5/26/2015
Alizé Pharma Presents Clinical Results From The AZP-531 Program At The American Diabetes Association 75th Scientific Sessions 5/26/2015
Alnylam (ALNY) Initiates Phase 1 Clinical Trial For ALN-AS1, An Investigational Rnai Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) For The Treatment Of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP) 5/26/2015
The Medicines Company (MDCO) Presents New Data Showing Remodeling Effect Of MDCO-216 On HDL Particles In Coronary Artery Disease Patients 5/26/2015
R-Tech Ueno: Announcement On Completion Of The Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096 5/26/2015
NewLink Genetics (NLNK) To Present Poster On Indoximod, An IDO Pathway Inhibitor, At ASCO Annual Meeting 5/26/2015
Cellular Biomedicine Group (CBMG) Announces Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program 5/22/2015
IRB Approves Additional Enrollment In Cellceutix (CTIX)'s Clinical Trial Of New Cancer Drug Candidate For Solid Tumors 5/22/2015
e-Therapeutics plc Release: Progress In ETS2101 Phase Ib Study 5/21/2015
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma 5/21/2015
EMD Serono, Inc. Release: Rebif (interferon beta-1a) Data At CMSC Annual Meeting Highlights Clinical And MRI Predictors For Long Term Outcomes 5/21/2015
ContraFect (CFRXU) Announces First Healthy Volunteer Dosed With CF-301 5/21/2015
Calithera Biosciences, Inc. (CALA) Reports Initial Phase I Data For CB-839 In Patients With Acute Leukemias 5/21/2015
Kite Pharma (KITE) Announces That The First Patient In Its Phase I/II Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, For Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) 5/21/2015
RestorGenex Announces Data On The Effect Of RES-529 In Pulmonary Fibrosis Models 5/21/2015
Prothena (PRTA) Announces Presentation Of Clinical Data From The Ongoing Phase I/II NEOD001 Study And Systemic Amyloidosis Patient Survey Results At 20th Congress Of The European Hematology Association 5/21/2015



//-->